Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn
- PMID: 10064674
- DOI: 10.1016/s0022-3476(99)70462-2
Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn
Abstract
Subcutaneous fat necrosis of the newborn (SCFN) is characterized by indurated violet skin nodules and, occasionally, life-threatening hypercalcemia. Current treatments of patients with SCFN-related hypercalcemia are often only partially successful and may be associated with prolonged hypercalcemia. We now report the use of etidronate, a bisphosphonate, to control hypercalcemia in an infant with SCFN.
Comment in
-
Expanding role of bisphosphonate therapy in children.J Pediatr. 1999 Mar;134(3):264-7. doi: 10.1016/s0022-3476(99)70447-6. J Pediatr. 1999. PMID: 10064659 Review. No abstract available.
-
Etidronate in subcutaneous fat necrosis of the newborn.J Pediatr. 1999 Oct;135(4):530-1. doi: 10.1016/s0022-3476(99)70183-6. J Pediatr. 1999. PMID: 10518093 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources